Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-01-04 Sale | 2022-01-06 4:12 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 245,469 | $42.58 | $10,452,334 | 4,484,728 (Indirect) | View |
| 2021-12-03 Sale | 2021-12-07 6:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 83,390 | $33.73 | $2,812,428 | 4,730,197 (Indirect) | View |
| 2021-11-30 Sale | 2021-12-02 6:53 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 139,773 | $34.47 | $4,817,417 | 4,813,587 (Indirect) | View |
| 2021-11-26 Sale | 2021-11-30 4:49 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 38,566 | $35.18 | $1,356,825 | 4,953,360 (Indirect) | View |
| 2021-11-22 Sale | 2021-11-24 6:38 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 129,617 | $36.61 | $4,744,666 | 5,007,597 (Indirect) | View |
| 2021-10-15 Sale | 2021-10-18 4:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 28,615 | $27.45 | $785,384 | 5,137,214 (Indirect) | View |
| 2021-10-12 Sale | 2021-10-14 5:26 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 95,002 | $27.21 | $2,584,606 | 5,165,829 (Indirect) | View |
| 2021-10-07 Sale | 2021-10-12 4:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 87,006 | $27.23 | $2,368,800 | 5,260,831 (Indirect) | View |
| 2021-10-01 Sale | 2021-10-05 4:31 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 46,130 | $27.05 | $1,247,590 | 5,347,837 (Indirect) | View |
| 2021-09-28 Sale | 2021-09-30 5:05 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 35,990 | $27 | $971,730 | 5,393,967 (Indirect) | View |
| 2021-09-23 Sale | 2021-09-27 5:51 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 89,476 | $27.76 | $2,484,094 | 5,429,957 (Indirect) | View |
| 2021-09-21 Sale | 2021-09-23 4:18 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 56,779 | $27.5 | $1,561,394 | 5,519,433 (Indirect) | View |
| 2021-09-16 Sale | 2021-09-20 6:30 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 152,711 | $28.38 | $4,334,452 | 5,576,212 (Indirect) | View |
| 2021-09-16 Sale | 2021-09-20 5:31 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 3,124 | $29.06 | $90,783 | 7,648,268 (Direct) | View |
| 2021-09-14 Sale | 2021-09-16 4:46 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 76,417 | $27.7 | $2,116,733 | 5,728,923 (Indirect) | View |
| 2021-09-14 Sale | 2021-09-16 4:45 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 13,531 | $29.17 | $394,635 | 7,651,392 (Direct) | View |
| 2021-09-09 Sale | 2021-09-13 7:02 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 96,456 | $28.32 | $2,731,460 | 5,805,340 (Indirect) | View |
| 2021-09-09 Sale | 2021-09-13 6:24 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 23,253 | $29.23 | $679,738 | 7,664,923 (Direct) | View |
| 2021-09-07 Sale | 2021-09-08 7:19 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 71,232 | $29.03 | $2,067,786 | 5,933,136 (Indirect) | View |
| 2021-09-03 Sale | 2021-09-08 6:20 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 48,640 | $29.2 | $1,420,394 | 7,688,176 (Direct) | View |
| 2021-08-31 Sale | 2021-09-02 5:26 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 24,309 | $29.5 | $717,218 | 7,736,816 (Direct) | View |
| 2021-08-27 Sale | 2021-08-31 4:47 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 44,358 | $29.24 | $1,296,884 | 7,761,125 (Direct) | View |
| 2021-08-23 Sale | 2021-08-25 7:42 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner | 105,894 | $29.29 | $3,101,344 | 7,805,483 (Direct) | View |
| 2021-08-11 Sale | 2021-08-12 4:55 pm | Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC MPM Oncology Impact Management LP 10% Owner | 2,510 | $29.05 | $72,916 | 7,911,377 (Direct) | View |
| 2021-05-28 Sale | 2021-06-02 6:09 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 57,494 | $20.63 | $1,186,190 | 6,328,095 (Indirect) | View |
| 2021-05-26 Sale | 2021-05-27 7:40 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 17,159 | $20.22 | $346,938 | 6,385,589 (Indirect) | View |
| 2021-05-21 Sale | 2021-05-24 8:11 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 15,907 | $20.18 | $321,030 | 6,402,748 (Indirect) | View |
| 2021-05-18 Sale | 2021-05-20 7:20 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 47,948 | $20.49 | $982,227 | 6,418,655 (Indirect) | View |
| 2021-05-13 Sale | 2021-05-17 5:23 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 16,421 | $20.05 | $329,314 | 6,466,603 (Indirect) | View |
| 2021-05-10 Sale | 2021-05-12 6:09 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 68,262 | $21.04 | $1,436,556 | 6,483,024 (Indirect) | View |
| 2021-05-04 Purchase | 2021-05-06 4:19 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Innovations Fund GP LLC MPM Oncology Impact Management GP LLC 10% Owner | 245,000 | $16 | $3,920,000 | 6,672,183 (Indirect) | View |
| 2021-05-05 Sale | 2021-05-06 4:05 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 10,172 | $22.52 | $229,107 | 6,551,286 (Indirect) | View |
| 2021-04-30 Sale | 2021-05-04 5:43 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 328,519 | $22.48 | $7,386,435 | 6,561,458 (Indirect) | View |
| 2021-04-27 Sale | 2021-04-29 5:46 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 130,143 | $21.99 | $2,861,368 | 6,889,977 (Indirect) | View |
| 2021-04-21 Sale | 2021-04-22 4:04 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 8,972 | $18.97 | $170,229 | 7,020,120 (Indirect) | View |
| 2021-04-16 Sale | 2021-04-20 6:07 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 38,152 | $19.04 | $726,550 | 7,029,092 (Indirect) | View |
| 2021-04-13 Sale | 2021-04-15 8:00 pm | Harpoon Therapeutics Inc. | HARP | GADICKE ANSBERT Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Impact Management GP LLC UBS Oncology Impact Fund L.P. 10% Owner | 38,556 | $20.16 | $777,359 | 7,067,244 (Indirect) | View |
| 2021-04-09 Sale | 2021-04-13 4:15 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. MPM Oncology Impact Management LP Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management GP LLC 10% Owner | 200 | $29.99 | $5,998 | 6,004,368 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-06-01 Other | 2023-06-05 4:37 pm | N/A N/A | TCR2 THERAPEUTICS INC. | TCRR | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner | 3,370,982 | $0 | 3,370,982 (Direct) | View |
| 2021-11-17 Other | 2021-11-24 6:38 pm | N/A N/A | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 15,671 | $0 | 5,007,597 (Indirect) | View |
| 2021-09-07 Other | 2021-09-08 7:19 pm | N/A N/A | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 31,340 | $0 | 5,933,136 (Indirect) | View |
| 2021-05-04 Conversion | 2021-05-06 4:19 pm | N/A N/A | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Innovations Fund GP LLC MPM Oncology Impact Management GP LLC 10% Owner | 57,683,698 | $0 | 6,672,183 (Indirect) | View |
Ownership | 2021-04-29 5:31 pm | N/A N/A | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM Oncology Impact Management LP MPM Oncology Innovations Fund GP LLC MPM Oncology Impact Management GP LLC 10% Owner | 0 | $0 | 6,486,087 (Indirect) | View |